Baxter, Momenta form follow-on biologics collaboration; terminated
Executive Summary
Baxter International Inc. and Momenta Pharmaceuticals Inc. (structural analysis of complex sugars) have agreed to develop and market as many as six follow-on biologics worldwide in multiple indications. Each partner has granted the other an exclusive license to its IP.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice